Martingale Asset Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $552K | Buy |
66,554
+8,706
| +15% | +$90.2K | 0.01% | 615 |
|
|
2025
Q4 | $715K | Buy |
57,848
+886
| +2% | +$9.49K | 0.02% | 539 |
|
|
2025
Q3 | $502K | Buy |
+56,962
| New | +$443K | 0.01% | 612 |
|
|
2024
Q3 | – | Sell |
-62,300
| Closed | -$425K | – | 802 |
|
|
2024
Q2 | $425K | Buy |
+62,300
| New | +$268K | 0.01% | 633 |
|
|
2023
Q4 | – | Sell |
-79,833
| Closed | -$271K | – | 804 |
|
|
2023
Q3 | $271K | Buy |
79,833
+31,721
| +66% | +$176K | 0.01% | 703 |
|
|
2023
Q2 | $354K | Sell |
48,112
-4,500
| -9% | -$41.7K | 0.01% | 675 |
|
|
2023
Q1 | $545K | Buy |
52,612
+11,508
| +28% | +$139K | 0.01% | 597 |
|
|
2022
Q4 | $485K | Buy |
41,104
+13,118
| +47% | +$203K | 0.01% | 620 |
|
|
2022
Q3 | $588K | Buy |
27,986
+6,397
| +30% | +$178K | 0.01% | 582 |
|
|
2022
Q2 | $671K | Hold |
21,589
| – | – | 0.01% | 579 |
|
|
2022
Q1 | $887K | Sell |
21,589
-500
| -2% | -$22.1K | 0.01% | 518 |
|
|
2021
Q4 | $961K | Buy |
22,089
+1,703
| +8% | +$77K | 0.01% | 505 |
|
|
2021
Q3 | $1.02M | Buy |
20,386
+8,071
| +66% | +$489K | 0.01% | 501 |
|
|
2021
Q2 | $776K | Buy |
+12,315
| New | +$791K | 0.01% | 478 |
|
|
2018
Q3 | – | Sell |
-7,406
| Closed | -$374K | – | 967 |
|
|
2018
Q2 | $374K | Sell |
7,406
-13,205
| -64% | -$688K | ﹤0.01% | 903 |
|
|
2018
Q1 | $1.09M | Hold |
20,611
| – | – | 0.01% | 712 |
|
|
2017
Q4 | $958K | Buy |
20,611
+2,205
| +12% | +$92.8K | 0.01% | 710 |
|
|
2017
Q3 | $745K | Buy |
18,406
+5,100
| +38% | +$185K | 0.01% | 784 |
|
|
2017
Q2 | $452K | Buy |
+13,306
| New | +$411K | 0.01% | 837 |
|
|
2016
Q2 | – | Sell |
-10,288
| Closed | -$374K | – | 839 |
|
|
2016
Q1 | $374K | Sell |
10,288
-1
| -0% | -$35 | 0.01% | 702 |
|
|
2015
Q4 | $412K | Sell |
10,289
-4,501
| -30% | -$157K | 0.01% | 692 |
|
|
2015
Q3 | $422K | Sell |
14,790
-9,322
| -39% | -$307K | 0.01% | 676 |
|
|
2015
Q2 | $795K | Sell |
24,112
-6,102
| -20% | -$189K | 0.02% | 578 |
|
|
2015
Q1 | $869K | Sell |
30,214
-1,300
| -4% | -$37.3K | 0.02% | 574 |
|
|
2014
Q4 | $859K | Sell |
31,514
-3,800
| -11% | -$90.6K | 0.02% | 572 |
|
|
2014
Q3 | $753K | Hold |
35,314
| – | – | 0.02% | 588 |
|
|
2014
Q2 | $794K | Sell |
35,314
-500
| -1% | -$11.6K | 0.02% | 584 |
|
|
2014
Q1 | $906K | Sell |
35,814
-1,000
| -3% | -$25.3K | 0.03% | 528 |
|
|
2013
Q4 | $847K | Sell |
36,814
-25,612
| -41% | -$534K | 0.03% | 606 |
|
|
2013
Q3 | $1.19M | Buy |
62,426
+1
| +0% | +$18 | 0.04% | 439 |
|
|
2013
Q2 | $901K | Buy |
+62,425
| New | +$904K | 0.03% | 536 |
|
Other funds holding EBS
VCM
PCM
VPM
Martingale Asset Management's EBS Position: Q1 2026 in Review
Martingale Asset Management increased its Emergent Biosolutions (EBS) stake by 15% in Q1 2026, buying an estimated $90.2K and bringing the position to 66,554 shares worth $552K. The position accounts for 0.01% of the portfolio, ranked #615.
Martingale Asset Management first reported a position in EBS in Q2 2013 and has held it in 31 quarters since. The position peaked at $1.19M in Q3 2013. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Martingale Asset Management held 66,554 shares of Emergent Biosolutions worth $552K as of Q1 2026.
- Martingale Asset Management bought 8,706 Emergent Biosolutions shares in Q1 2026, an estimated $90.2K.
- Emergent Biosolutions made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #615 holding.
- Martingale Asset Management first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 31 quarters since.
- Martingale Asset Management's Emergent Biosolutions position peaked at $1.19M in Q3 2013.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.